Please login to the form below

Not currently logged in
Email:
Password:

Lu AE58054

This page shows the latest Lu AE58054 news and features for those working in and with pharma, biotech and healthcare.

Lundbeck trial failure dashes hopes in Alzheimer's once again

Lundbeck trial failure dashes hopes in Alzheimer's once again

Idalopirdine (Lu AE58054) appeared to be safe and showed evidence of "weak efficacy" in the phase III STARSHINE study, which enrolled patients with mild to moderate Alzheimer's.

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    The first phase III study in patients with mild-to-moderate Alzheimer's disease will assess Lu AE58054 as an adjunct treatment to donepezil. ... The Lu AE58054 deal comes out of an already successful relationship between Lundbeck and Otsuka.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics